An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 [mipomersen sodium] in Subjects With Familial Hypercholesterolemia.

Trial Profile

An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 [mipomersen sodium] in Subjects With Familial Hypercholesterolemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Mipomersen (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type II
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Sep 2014 Results of a retrospective analysis including patients with both homozygous and heterozygous familial hypercholesterolemia treated for one year were presented at the 2014 European Society of Cardiology Congress, according to an Isis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top